Stryker (NYSE:SYK) PT Raised to $370.00 at Evercore ISI

Stryker (NYSE:SYK) had its target price boosted by research analysts at Evercore ISI from $340.00 to $370.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage presently has an “outperform” rating on the medical technology company’s stock. Evercore ISI’s target price would suggest a potential upside of 5.41% from the stock’s current price.

Several other analysts also recently weighed in on the stock. Citigroup lifted their price target on shares of Stryker from $362.00 to $406.00 and gave the company a “buy” rating in a research note on Wednesday. Roth Mkm lifted their price objective on shares of Stryker from $345.00 to $348.00 and gave the company a “buy” rating in a report on Wednesday, January 31st. Truist Financial lifted their price objective on shares of Stryker from $330.00 to $345.00 and gave the company a “hold” rating in a report on Wednesday, January 31st. Royal Bank of Canada reissued an “outperform” rating and set a $360.00 price objective on shares of Stryker in a report on Thursday, February 15th. Finally, Wells Fargo & Company lifted their price objective on shares of Stryker from $336.00 to $364.00 and gave the company an “overweight” rating in a report on Wednesday, January 31st. Three analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat.com, Stryker currently has a consensus rating of “Moderate Buy” and an average target price of $335.27.

Stryker Stock Up 1.0 %

Shares of NYSE SYK opened at $351.02 on Thursday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.58 and a quick ratio of 0.97. The company has a market cap of $133.55 billion, a P/E ratio of 42.55, a PEG ratio of 2.86 and a beta of 0.89. Stryker has a 1 year low of $249.98 and a 1 year high of $361.41. The firm has a 50-day simple moving average of $348.29 and a two-hundred day simple moving average of $307.92.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.27 by $0.19. The business had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. Stryker had a net margin of 15.44% and a return on equity of 22.99%. The firm’s quarterly revenue was up 11.8% compared to the same quarter last year. During the same quarter last year, the firm earned $3.00 earnings per share. Research analysts anticipate that Stryker will post 11.86 earnings per share for the current year.

Insider Activity at Stryker

In related news, CAO William E. Berry, Jr. sold 7,690 shares of the business’s stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the completion of the transaction, the chief accounting officer now directly owns 3,675 shares in the company, valued at $1,317,414. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of the company’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $358.48, for a total value of $2,756,711.20. Following the completion of the transaction, the chief accounting officer now owns 3,675 shares in the company, valued at $1,317,414. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 201,146 shares of the company’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $342.90, for a total transaction of $68,972,963.40. Following the completion of the transaction, the director now owns 3,755,128 shares of the company’s stock, valued at approximately $1,287,633,391.20. The disclosure for this sale can be found here. Insiders sold 212,109 shares of company stock worth $72,845,768 over the last three months. Company insiders own 5.90% of the company’s stock.

Institutional Trading of Stryker

Institutional investors and hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC grew its stake in Stryker by 15.0% during the 1st quarter. GAMMA Investing LLC now owns 1,324 shares of the medical technology company’s stock valued at $474,000 after acquiring an additional 173 shares in the last quarter. Los Angeles Capital Management LLC grew its stake in Stryker by 18.9% during the 1st quarter. Los Angeles Capital Management LLC now owns 376,195 shares of the medical technology company’s stock valued at $134,629,000 after acquiring an additional 59,832 shares in the last quarter. NBC Securities Inc. grew its stake in Stryker by 420.7% during the 1st quarter. NBC Securities Inc. now owns 10,024 shares of the medical technology company’s stock valued at $3,587,000 after acquiring an additional 8,099 shares in the last quarter. CWM LLC grew its stake in Stryker by 3.6% during the 1st quarter. CWM LLC now owns 14,476 shares of the medical technology company’s stock valued at $5,180,000 after acquiring an additional 497 shares in the last quarter. Finally, Trust Co. of Toledo NA OH increased its holdings in shares of Stryker by 6.8% during the 1st quarter. Trust Co. of Toledo NA OH now owns 1,574 shares of the medical technology company’s stock worth $563,000 after buying an additional 100 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.